<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071615</url>
  </required_header>
  <id_info>
    <org_study_id>2012-003882-17</org_study_id>
    <secondary_id>DRKS00005219</secondary_id>
    <nct_id>NCT02071615</nct_id>
  </id_info>
  <brief_title>Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers</brief_title>
  <acronym>MKM</acronym>
  <official_title>Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Volkswagen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      In this study the investigators compare three stimulants to each other. The effects of these&#xD;
      agents on cognitive performance (eg, attention and memory) and on the brain are being&#xD;
      measured. The hypothesis is that stimulants will have a positive effect on cognitive&#xD;
      performance.&#xD;
&#xD;
      Each study participant will receive once a placebo and once methylphenidate or modafinil or&#xD;
      caffeine. Methylphenidate (also known as Ritalin ®) is a drug that is used in the treatment&#xD;
      of attention deficit / hyperactivity disorder (ADHD) in children, adolescents and adults.&#xD;
      Modafinil ( Vigil ®) is a drug used in the treatment of narcolepsy (sleeping sickness). In&#xD;
      the study. These substances are given in the study only once and in the dosages in which is&#xD;
      also used for the treatment of the above diseases. In the case of caffeine , the dosage&#xD;
      corresponds to two cups of coffee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting state parameters of functional magnetic resonance imaging (fMRI) as a measure of brain activity</measure>
    <time_frame>1 hour</time_frame>
    <description>The resting state parameters that will be measured are regional homogeneity (ReHo) und amplitude of low frequency fluctuation (ALFF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance on cognitive tests</measure>
    <time_frame>4 hours</time_frame>
    <description>A test battery covering several cognitive domaines is being used including: digit-span-Task, dual n-back, psychomotor vigilance task, reasoning task, memory task (free recall/ recognition), mental speed task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Methylphenidate and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo or Methylphenidate 20 mg tablet given once by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>modafinil and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo or modafinil 200mg tablet given once by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>caffein and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo or caffein 200mg tablet given once by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate 20 mg tablet given once by mouth</intervention_name>
    <description>3-arm, single-drug dosage comparison study</description>
    <arm_group_label>Methylphenidate and placebo</arm_group_label>
    <other_name>Ritalin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil 200mg tablet given once by mouth</intervention_name>
    <description>3-arm, single-drug dosage comparison study</description>
    <arm_group_label>modafinil and placebo</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffein 200mg tablet given once by mouth</intervention_name>
    <description>3-arm, single-drug dosage comparison study</description>
    <arm_group_label>caffein and placebo</arm_group_label>
    <other_name>Coffeinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Methylphenidate and placebo</arm_group_label>
    <arm_group_label>caffein and placebo</arm_group_label>
    <arm_group_label>modafinil and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  18 - 35 years&#xD;
&#xD;
          -  Written consent (according to Arzneimittelgesetz (AMG) § 40 (1) 3b)&#xD;
&#xD;
          -  Good knowledge of German&#xD;
&#xD;
          -  Right-handedness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to the study medication&#xD;
&#xD;
          -  All contraindications to the study medication: arrhythmia, hyperthyroidism , glaucoma&#xD;
             , pheochromocytoma , congestive heart failure , diabetes mellitus, known liver and&#xD;
             kidney dysfunction, vascular disease , angina, haemodynamically significant congenital&#xD;
             heart disease , cardiomyopathy , myocardial infarction, channelopathies, arterial&#xD;
             hypertension , cerebrovascular diseases , such as cerebral aneurysm , vascular&#xD;
             abnormalities , including vasculitis and stroke.&#xD;
&#xD;
          -  Participation in other clinical trials during or within one month prior to this&#xD;
             clinical trial&#xD;
&#xD;
          -  Medical or psychological circumstances that may endanger the proper conduct of the&#xD;
             trial&#xD;
&#xD;
          -  Existing serious somatic diseases, even if they are not covered by the&#xD;
             contraindications according to product information&#xD;
&#xD;
          -  Existing psychiatric disorders and psychiatric disorders in prehistory&#xD;
&#xD;
          -  Smoker or ex-smoker for less than 5 years&#xD;
&#xD;
          -  Regular caffeine consumption &gt; 4 cups per day&#xD;
&#xD;
          -  Subjects with irregular day -night rhythm (eg shift workers )&#xD;
&#xD;
          -  Unwillingness to the storage and disclosure of pseudonymous data as part of the&#xD;
             clinical trial&#xD;
&#xD;
          -  Accommodation in an institution by court or administrative order (according to AMG §&#xD;
             40 (1) 4 )&#xD;
&#xD;
          -  MRI contraindications ( eg pacemakers , metallic or electronic implants , metallic&#xD;
             splinters , tinnitus, surgical clips )&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Repantis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry and Psychotherapy, Charité - University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Charité - University</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>February 15, 2014</study_first_submitted>
  <study_first_submitted_qc>February 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Dimitris Repantis</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Brain Activity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

